Watts Gwilliam & Co. LLC Acquires Shares of 356 Thermo Fisher Scientific Inc. (NYSE:TMO)

Watts Gwilliam & Co. LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 356 shares of the medical research company’s stock, valued at approximately $212,000.

A number of other hedge funds have also recently modified their holdings of the company. Pinnacle Bancorp Inc. increased its position in shares of Thermo Fisher Scientific by 4.1% in the third quarter. Pinnacle Bancorp Inc. now owns 733 shares of the medical research company’s stock valued at $453,000 after acquiring an additional 29 shares during the period. WealthBridge Investment Counsel Inc. increased its position in shares of Thermo Fisher Scientific by 2.1% during the third quarter. WealthBridge Investment Counsel Inc. now owns 11,117 shares of the medical research company’s stock valued at $6,877,000 after buying an additional 225 shares during the period. Quotient Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 3.5% during the third quarter. Quotient Wealth Partners LLC now owns 1,254 shares of the medical research company’s stock valued at $776,000 after buying an additional 42 shares during the period. SS&H Financial Advisors Inc. purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $205,000. Finally, Steigerwald Gordon & Koch Inc. purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at about $210,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. TD Cowen boosted their price target on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Bank of America upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Stephens started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective on the stock. Finally, Evercore ISI upped their price objective on shares of Thermo Fisher Scientific from $605.00 to $630.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $653.72.

Thermo Fisher Scientific Stock Performance

TMO opened at $596.92 on Friday. The stock has a market capitalization of $227.85 billion, a price-to-earnings ratio of 38.29, a PEG ratio of 3.84 and a beta of 0.77. The company has a fifty day moving average of $607.73 and a 200 day moving average of $583.34. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. During the same quarter last year, the business earned $5.15 earnings per share. Thermo Fisher Scientific’s quarterly revenue was down 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at $10,747,403.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,084 shares of company stock worth $14,094,292 over the last 90 days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.